Tyrosine-Protein Kinase ABL1 (ABL1) Antibody (Biotin)

Este producto es parte de ABL - Tyrosine-protein kinase ABL
Product Graph
169€ (20 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Tyrosine-Protein Kinase ABL1 (ABL1) Antibody (Biotin)
category
Primary Antibodies
provider
Abbexa
reference
abx106036
tested applications
ELISA

Description

Tyrosine-Protein Kinase ABL1 Antibody (Biotin) is a Rabbit Polyclonal antibody against Tyrosine-Protein Kinase ABL1 conjugated to Biotin.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Tyrosine-Protein Kinase ABL1 (ABL1)
Host
Rabbit
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Biotin
Isotype
IgG
Purity
> 95%
Purification
Purified by Protein G.
Size 1
20 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
1 mg
Form
Liquid
Tested Applications
ELISA
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P00519
Gene ID
25
NCBI Accession
NP_005148.2, NM_005157.5
OMIM
189980
Alias
ABL,BCR-ABL,CHDSKM,ABL proto-oncogene 1 non-receptor tyrosine kinase
Background
Antibody anti-ABL1
Status
RUO

Descripción

ABL1 is a non-receptor tyrosine kinase involved in various cellular processes, including cytoskeletal remodeling, cell migration, DNA damage response, and signal transduction. It is ubiquitously expressed and localized in both the nucleus and cytoplasm, where it interacts with numerous signaling proteins. ABL1 contains SH2 and SH3 domains, a kinase domain, and regulatory regions that facilitate its interaction with other proteins and its activation in response to cellular stimuli. Dysregulation of ABL1, particularly through chromosomal translocations such as the Philadelphia chromosome, results in the BCR-ABL1 fusion protein, which drives chronic myeloid leukemia (CML) by promoting uncontrolled cell proliferation and survival. Targeting ABL1 with tyrosine kinase inhibitors, such as imatinib, has revolutionized the treatment of CML and highlighted its role as a key therapeutic target. Beyond cancer, ABL1 contributes to cellular responses to oxidative stress, DNA damage repair, and cytoskeletal dynamics, underscoring its importance in maintaining cellular homeostasis and responding to environmental challenges.

Related Products

EH4452

Human ABL1(Tyrosine-protein kinase ABL1) ELISA Kit

Ver Producto
abx000091

ABL1 (pY245) Antibody

ABL1 (pY245) Antibody is a Rabbit Polyclonal antibody against ABL1 (pY245). The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11.

Ver Producto
abx000093

ABL1 (pY204) Antibody

ABL1 (pY204) Antibody is a Rabbit Polyclonal antibody against ABL1 (pY204). The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11.

Ver Producto